Equities

Immix Biopharma Inc

IMMX:NAQ

Immix Biopharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.83
  • Today's Change0.05 / 2.81%
  • Shares traded41.49k
  • 1 Year change-44.38%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 16:49 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments181318
Total Receivables, Net1.170.260.03
Total Inventory------
Prepaid expenses1.061.210.52
Other current assets, total0.04----
Total current assets201518
Property, plant & equipment, net0.050.000.01
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets--0.01--
Total assets201518
LIABILITIES
Accounts payable1.43----
Accrued expenses2.2900.01
Notes payable/short-term debt000.05
Current portion long-term debt/capital leases------
Other current liabilities, total----0
Total current liabilities3.721.270.20
Total long term debt000
Total debt000.05
Deferred income tax------
Minority interest(0.2)----
Other liabilities, total00.48--
Total liabilities3.521.750.20
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital705148
Retained earnings (accumulated deficit)(53)(38)(30)
Treasury stock - common(0.1)(0.1)--
Unrealized gain (loss)------
Other equity, total0.130.090.13
Total equity161318
Total liabilities & shareholders' equity201518
Total common shares outstanding201413
Treasury shares - common primary issue0.070.070
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.